Literature DB >> 22922738

Impact of rapamycin on peritoneal fibrosis and transport function.

T Xu1, J Y Xie, W M Wang, H Ren, N Chen.   

Abstract

OBJECTIVES: To observe the impact of rapamycin on peritoneal fibrosis and peritoneal transport function in a rat model of peritoneal fibrosis.
METHODS: A total of 40 male SD rats were randomly divided into five groups, with 8 rats in each group. Group N was the normal control. In group NS, the rats were injected daily with 20 ml of saline intraperitoneally. In groups GLU, L-RAPA and H-RAPA, rats were injected daily with 20 ml of 4.25% peritoneal dialysis solution intraperitoneally, together with 150 µg of lipopolysaccharide on days 1, 3, 5 and 7. Rapamycin was administered to groups L-RAPA (250 µg/day) and H-RAPA (500 µg/day) intragastrically. On days 21 and 35, 4 rats from each group were selected to evaluate their peritoneal transport function (ultrafiltration volume, D(2)/D(0) ratio). The parietal peritoneal membrane from the rats was used for pathological study. Light microscopy (HE staining and VG staining) was used to assess the morphological changes. The expression levels of Col I, α-SMA, TGF-β(1), Reca and Ki67 in the parietal peritoneal membrane were observed by immunohistochemistry.
RESULTS: The ultrafiltration volume and D(2)/D(0) ratio decreased in group GLU compared with group N on day 21 (p < 0.05) and further decreased on day 35 (p < 0.01), whereas such a significant change was not observed in group L-RAPA or H-RAPA. Furthermore, severe loss of the peritoneal mesothelial cells, exposure of the collagen matrix under the mesothelial cells, and infiltration of fibroblasts and various inflammatory cells were detected in group GLU on days 21 and 35. The thickness of the submesothelial compact zone significantly increased in group GLU compared with group N (p < 0.01). However, in groups L-RAPA and H-RAPA, the morphological changes were clearly alleviated, and the submesothelial compact zone was thinner than in group GLU (p < 0.01). The expression levels of Col I, α-SMA, TGF-β(1), Ki67 and Reca in the peritoneal membrane were significantly increased in group GLU compared with group N on days 21 and 35 (p < 0.01), whereas these changes were significantly attenuated in groups L-RAPA and H-RAPA compared with group GLU (p < 0.01).
CONCLUSIONS: Rapamycin had an obvious effect in inhibiting peritoneal fibrosis and improving peritoneal membrane transport function.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922738     DOI: 10.1159/000339814

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  7 in total

1.  Abatacept as a therapeutic option in the treatment of encapsulated peritoneal sclerosis: an experimental rat model.

Authors:  Latife Bircan; Suleyman Karakose; Hatice Unverdi; Ayşe Zeynep Bal; Selman Unverdi; Murat Duranay
Journal:  Int Urol Nephrol       Date:  2017-02-11       Impact factor: 2.370

Review 2.  A review of rodent models of peritoneal dialysis and its complications.

Authors:  Ji Wang; Shujun Liu; Hongyu Li; Jing Sun; Sijin Zhang; Xiaohong Xu; Yingying Liu; Yangwei Wang; Lining Miao
Journal:  Int Urol Nephrol       Date:  2014-11-26       Impact factor: 2.370

3.  mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration.

Authors:  Shailesh Agarwal; David Cholok; Shawn Loder; John Li; Christopher Breuler; Michael T Chung; Hsiao Hsin Sung; Kavitha Ranganathan; Joe Habbouche; James Drake; Joshua Peterson; Caitlin Priest; Shuli Li; Yuji Mishina; Benjamin Levi
Journal:  JCI Insight       Date:  2016-12-08

4.  Low molecular weight heparin (LMWH) improves peritoneal function and inhibits peritoneal fibrosis possibly through suppression of HIF-1α, VEGF and TGF-β1.

Authors:  Juan Li; Zhi Yong Guo; Xian Hua Gao; Qi Bian; Meng Jia; Xue Li Lai; Tie Yun Wang; Xiao Lu Bian; Hai Yan Wang
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

5.  Rapamycin Protects from Type-I Peritoneal Membrane Failure Inhibiting the Angiogenesis, Lymphangiogenesis, and Endo-MT.

Authors:  Guadalupe Tirma González-Mateo; Anna Rita Aguirre; Jesús Loureiro; Hugo Abensur; Pilar Sandoval; José Antonio Sánchez-Tomero; Gloria del Peso; José Antonio Jiménez-Heffernan; Vicente Ruiz-Carpio; Rafael Selgas; Manuel López-Cabrera; Abelardo Aguilera; Georgios Liappas
Journal:  Biomed Res Int       Date:  2015-11-25       Impact factor: 3.411

6.  The effect of rituximab on encapsulated peritoneal sclerosis in an experimental rat model

Authors:  Süleyman Karaköse; Ayşe Zeynep Bal; Eylem Pinar Eser; Murat Duranay
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

Review 7.  IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis.

Authors:  Vanessa Marchant; Antonio Tejera-Muñoz; Laura Marquez-Expósito; Sandra Rayego-Mateos; Raul R Rodrigues-Diez; Lucia Tejedor; Laura Santos-Sanchez; Jesús Egido; Alberto Ortiz; Jose M Valdivielso; Donald J Fraser; Manuel López-Cabrera; Rafael Selgas; Marta Ruiz-Ortega
Journal:  Biomolecules       Date:  2020-09-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.